AntagomiR directed against miR-20a restores functional BMPR2 signalling and prevents vascular remodelling in hypoxia-induced pulmonary hypertension

European Heart Journal

Volumn 35, Issue 45, 2014, Pages 3203-3211

  Brock, Matthias ^a   Samillan, Victor J ^b   Trenkmann, Michelle ^a   Schwarzwald, Colin ^b   Ulrich, Silvia ^a   Gay, Renate E ^a   Gassmann, Max ^b   Ostergaard, Louise ^b   Gay, Steffen ^a   Speich, Rudolf ^a   Huber, Lars C ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b UNIVERSITY OF ZURICH   (Switzerland)

Author keywords

AntagomiR; BMPR2; MicroRNA; Pulmonary hypertension; Vascular remodelling

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; ANTAGOMIR; BONE MORPHOGENETIC PROTEIN 2; BONE MORPHOGENETIC PROTEIN RECEPTOR 2; INHIBITOR OF DIFFERENTIATION 1; INHIBITOR OF DIFFERENTIATION 2; MICRORNA 20A; SMAD5 PROTEIN; ANTIHYPERTENSIVE AGENT; CHOLESTEROL; MICRORNA; MIRN20 MICRORNA, MOUSE; OLIGORIBONUCLEOTIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERIAL SMOOTH MUSCLE CELL; ARTERIAL WALL THICKNESS; ARTERIOLE; ARTERY MUSCLE; ARTICLE; BLOOD ANALYSIS; BODY WEIGHT; BRDU ASSAY; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; ERYTHROCYTOSIS; EXPERIMENTAL HYPOXIA; GENE EXPRESSION; HEART AFTERLOAD; HEART LEFT VENTRICLE VOLUME; HEART RIGHT VENTRICLE HYPERTROPHY; HEART RIGHT VENTRICLE VOLUME; HEART WEIGHT; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; LUNG BLOOD VESSEL; LUNG PARENCHYMA; MALE; MORPHOMETRICS; MOUSE; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PULMONARY ARTERIAL VASCULAR REMODELLING; PULMONARY ARTERY; PULMONARY HYPERTENSION; QUANTITATIVE ANALYSIS; SIGNAL TRANSDUCTION; SMOOTH MUSCLE FIBER; UPREGULATION; VASCULAR REMODELING; VASCULAR SMOOTH MUSCLE; VASCULAR SMOOTH MUSCLE CELL; WESTERN BLOTTING; ANALOGS AND DERIVATIVES; ANIMAL; ANOXIA; ANTAGONISTS AND INHIBITORS; COMPLICATION; CORONARY ARTERY BLOOD FLOW; CYTOLOGY; DISEASE MODEL; DRUG EFFECTS; GENETIC TRANSFECTION; HYPERTENSION, PULMONARY; IN VITRO STUDY; LUNG CIRCULATION; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY;

ANIMALS; ANOXIA; ANTIHYPERTENSIVE AGENTS; BONE MORPHOGENETIC PROTEIN RECEPTORS, TYPE II; CELL PROLIFERATION; CHOLESTEROL; CORONARY CIRCULATION; DISEASE MODELS, ANIMAL; HYPERTENSION, PULMONARY; HYPERTROPHY, RIGHT VENTRICULAR; IN VITRO TECHNIQUES; MALE; MICE; MICRORNAS; MUSCLE, SMOOTH, VASCULAR; OLIGORIBONUCLEOTIDES; PULMONARY CIRCULATION; SIGNAL TRANSDUCTION; TRANSFECTION; VASCULAR REMODELING;

EID: 84922347131     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/ehs060     Document Type: Article

References (23)

1. Lane KB, Machado RD, Pauciulo MW, Thomson JR, Phillips JA III, Loyd JE, Nichols WC, Trembath RC. Heterozygous germline mutations in BMPR2, encoding a TGF-beta receptor, cause familial primary pulmonary hypertension. Nat Genet 2000;26:81-84.
2. Machado RD, Eickelberg O, Elliott CG, Geraci MW, Hanaoka M, Loyd JE, Newman JH, Phillips JA III, Soubrier F, Trembath RC, Chung WK. Genetics and genomics of pulmonary arterial hypertension. J Am Coll Cardiol 2009;54(1 Suppl):S32-S42.
3. Atkinson C, Stewart S, Upton PD, Machado R, Thomson JR, Trembath RC, Morrell NW. Primary pulmonary hypertension is associated with reduced pulmonary vascular expression of type II bone morphogenetic protein receptor. Circulation 2002;105:1672-1678.
4. Takahashi H, Goto N, Kojima Y, Tsuda Y, Morio Y, Muramatsu M, Fukuchi Y. Downregulation of type II bone morphogenetic protein receptor in hypoxic pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol 2006;290:L450-L458.
5. Morty RE, Nejman B, Kwapiszewska G, Hecker M, Zakrzewicz A, Kouri FM, Peters DM, Dumitrascu R, Seeger W, Knaus P, Schermuly RT, Eickelberg O. Dysregulated bone morphogenetic protein signaling in monocrotaline-induced pulmonary arterial hypertension. Arterioscler Thromb Vasc Biol 2007;27:1072-1078.
6. Long L, Crosby A, Yang X, Southwood M, Upton PD, Kim DK, Morrell NW. Altered bone morphogenetic protein and transforming growth factor-beta signaling in rat models of pulmonary hypertension: potential for activin receptor-like kinase-5 inhibition in prevention and progression of disease. Circulation 2009; 119:566-576.
7. Dewachter L, Adnot S, Guignabert C, Tu L, Marcos E, Fadel E, Humbert M, Dartevelle P, Simonneau G, Naeije R, Eddahibi S. Bone morphogenetic protein signalling in heritable versus idiopathic pulmonary hypertension. Eur Respir J 2009;34:1100-1110.
8. Carthew RW. Gene regulation by microRNAs. Curr Opin Genet Dev 2006;16: 203-208.
9. Friedman RC, Farh KK, Burge CB, Bartel DP. Most mammalian mRNAs are conserved targets of microRNAs. Genome Res 2009;19:92-105.
10. Sayed D, Abdellatif M. MicroRNAs in development and disease. Physiol Rev 2011; 91:827-887.
11. Krutzfeldt J, Rajewsky N, Braich R, Rajeev KG, Tuschl T, Manoharan M, Stoffel M. Silencing of microRNAs in vivo with 'antagomirs'. Nature 2005;438:685-689.
12. Brock M, Trenkmann M, Gay RE, Michel BA, Gay S, Fischler M, Ulrich S, Speich R, Huber LC. Interleukin-6 modulates the expression of the bone morphogenic protein receptor type II through a novel STAT3-microRNA cluster 17/92 pathway. Circ Res 2009;104:1184-1191.
13. Caruso P, MacLean MR, Khanin R, McClure J, Soon E, Southgate M, MacDonald RA, Greig JA, Robertson KE, Masson R, Denby L, Dempsie Y, Long L, Morrell NW, Baker AH. Dynamic changes in lung microRNA profiles during the development of pulmonary hypertension due to chronic hypoxia and monocrotaline. Arterioscler Thromb Vasc Biol 0000;30:716-723.
14. Abe J. Bone morphogenetic protein (BMP) family, SMAD signaling and Id helix-loop-helix proteins in the vasculature: the continuous mystery of BMPs pleotropic effects. J Mol Cell Cardiol 2006;41:4-7.
15. Lopez-Rovira T, Chalaux E, Massague J, Rosa JL, Ventura F. Direct binding of Smad1 and Smad4 to two distinct motifs mediates bone morphogenetic proteinspecific transcriptional activation of Id1 gene. J Biol Chem 2002;277:3176-3185.
16. Lewis BP, Burge CB, Bartel DP. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell 2005; 120:15-20.
17. Pullamsetti SS, Doebele C, Fischer A, Savai R, Kojonazarov B, Dahal BK, Ghofrani HA, Weissmann N, Grimminger F, Bonauer A, Seeger W, Zeiher AM, Dimmeler S, Schermuly RT. Inhibition of microRNA-17 improves lung and heart function in experimental pulmonary hypertension. Am J Respir Crit Care Med 2012;185:409-419.
18. Care A, Catalucci D, Felicetti F, Bonci D, Addario A, Gallo P, Bang ML, Segnalini P, Gu Y, Dalton ND, Elia L, Latronico MV, Hoydal M, Autore C, Russo MA, Dorn GW II, Ellingsen O, Ruiz-Lozano P, Peterson KL, Croce CM, Peschle C, Condorelli G. MicroRNA-133 controls cardiac hypertrophy. Nat Med 2007;13: 613-618.
19. Thum T, Gross C, Fiedler J, Fischer T, Kissler S, Bussen M, Galuppo P, Just S, Rottbauer W, Frantz S, Castoldi M, Soutschek J, Koteliansky V, Rosenwald A, Basson MA, Licht JD, Pena JT, Rouhanifard SH, Muckenthaler MU, Tuschl T, Martin GR, Bauersachs J, Engelhardt S. MicroRNA-21 contributes to myocardial disease by stimulating MAP kinase signalling in fibroblasts. Nature 2008;456: 980-984.
20. Wang J, Song Y, Zhang Y, Xiao H, Sun Q, Hou N, Guo S,Wang Y, Fan K, Zhan D, Zha L, Cao Y, Li Z, Cheng X, Yang X. Cardiomyocyte overexpression of miR-27b induces cardiac hypertrophy and dysfunction in mice. Cell Res 2012;22:516-527.
21. Wong GA, Tang V, El-Sabeawy F, Weiss RH. BMP-2 inhibits proliferation of human aortic smooth muscle cells via p21Cip1/Waf1. Am J Physiol Endocrinol Metab 2003;284:E972-E979.
22. Yang J, Li X, Al-Lamki RS, Southwood M, Zhao J, Lever AM, Grimminger F, Schermuly RT, Morrell NW. Smad-dependent and smad-independent induction of id1 by prostacyclin analogues inhibits proliferation of pulmonary artery smooth muscle cells in vitro and in vivo. Circ Res 2010;107:252-262.
23. Inomata M, Tagawa H, Guo YM, Kameoka Y, Takahashi N, Sawada K. MicroRNA-17-92 down-regulates expression of distinct targets in different B-cell lymphoma subtypes. Blood 2009;113:396-402.